1. Enhancement of Delta Aminolevulinic Acid-Photodynamic Therapy In Vivo by Decreasing Tumor pH With Glucose and Amiloride
- Author
-
Ludovic Bourré, Nathalie Rousset, Benoît Piot, Sabine Eléouet, Thierry Patrice, Véronique Vonarx, P. Lenz, and Jérome Carré
- Subjects
Male ,medicine.medical_specialty ,medicine.drug_class ,medicine.medical_treatment ,Intraperitoneal injection ,Protoporphyrins ,Photodynamic therapy ,Adenocarcinoma ,Amiloride ,Mice ,chemistry.chemical_compound ,In vivo ,Internal medicine ,medicine ,Animals ,Humans ,Acid-Base Equilibrium ,Protoporphyrin IX ,business.industry ,Aminolevulinic Acid ,Hydrogen-Ion Concentration ,Endocrinology ,Photochemotherapy ,Otorhinolaryngology ,chemistry ,Epidermoid carcinoma ,Potassium-sparing diuretic ,Colonic Neoplasms ,Toxicity ,business ,HT29 Cells ,Neoplasm Transplantation ,medicine.drug - Abstract
Objectives/Hypothesis Delta aminolevulinic acid (ALA)–induced protoporphyrin IX (PpIX) is a fluorescent sensitizer that permits detection and treatment of squamous cell carcinoma of the oral cavity. An exogenously induced decrease in tissue pH was evaluated for its effect in enhancing cellular uptake of ALA and facilitating its transformation into PpIX. Study Design Mice grafted with HT29 colonic cancers had been given glucose and amiloride to modify the pH of tissues. Influence of pH changes has been evaluated on ALA-induced PPIX fluorescence by optic fiber spectrofluorimetry as well as on tumor growth. Methods Results: The pH in HT 29 tumor decreased from 7.1 to 6.67 (P
- Published
- 2001